Brain tumors

New England Journal of Medicine

Volumn 344, Issue 2, 2001, Pages 114-123

  DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; ETOPOSIDE; GADOLINIUM; LOMUSTINE; MELPHALAN; NITROSOUREA DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; THIOTEPA;

ARTICLE; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER REGISTRY; CLINICAL FEATURE; CONTRAST ENHANCEMENT; GLIOMA; HUMAN; IONIZING RADIATION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MENINGIOMA; PRIORITY JOURNAL; RADIODIAGNOSIS; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOMA; HUMANS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MENINGEAL NEOPLASMS; MENINGIOMA;

EID: 0035843243     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200101113440207     Document Type: Article

References (88)

1. Cancer statistics, 1999
2. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota
3. Descriptive epidemiology of primary brain and CNS tumors: Results from the Central Brain Tumor Registry of the United States, 1990-1994
4. The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly
5. Brain and other central nervous system cancers: Recent trends in incidence and mortality
6. Rising primary malignant brain tumor mortality in the elderly: A manifestation of differential survival
7. Meningiomas after radiotherapy for tinea capitis - Still no history
8. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital
9. Nutritional factors in the etiology of brain tumors: Potential role of nitrosamines, fat, and cholesterol
10. Nonionizing electromagnetic fields and cancer: A review
11. Incidence of intracranial tumors following hospitalization for head injuries (Denmark)
12. Cellular-telephone use and brain tumors
13. Headaches in patients with brain tumors: A study of 111 patients
14. Lymphomatous meningitis presenting as atypical cluster headache
15. Primary and secondary glioblastomas: From concept to clinical diagnosis
16. Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected tumor cells
17. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study
18. Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors: An analysis of DNA content (ploidy), cellular proliferation, and p53 expression
19. A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours
20. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the lowgrade glioma
21. The role of surgery in low grade gliomas
22. Suspected low-grade glioma: Is deferring treatment safe?
23. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844
24. A prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a NCCTG-RTOG-ECOG study
25. Immediate postoperative radiotherapy in low grade glioma improves progression free survival, but not overall survival: Preliminary results of an EORTC/MRC randomized phase III study
26. Treatment and survival of low-grade astrocytoma in adults - 1977-1988
27. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography
28. Pretreatment factors predict overall survival for patients with low-grade glioma: A recursive partitioning analysis
29. Gliomatosis cerebri presenting as intractable epilepsy during early childhood
30. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms
31. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
32. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
33. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas
34. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas
35. Extent of resection as a prognostic variable in the treatment of gliomas
36. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials
37. Morbidity and mortality of craniotomy for excision of supratentorial gliomas
38. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: A cooperative clinical trial
39. Brachytherapy for brain tumor
40. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas
41. Fractionated stereotactic radiotherapy of small intracranial malignancies
42. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
43. Malignant glioma: Who benefits from adjuvant chemotherapy?
44. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
45. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy
46. Multi-drug versus single agent chemotherapy for high grade astrocytoma: Results of a meta-analysis
47. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
48. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
49. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
50. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
51. Morphologic and molecular genetic aspects of oligodendroglial neoplasms
52. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
53. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas
54. Successful chemotherapy for recurrent malignant oligodendroglioma
55. Chemotherapy for anaplastic oligodendroglioma
56. Salvage chemotherapy for oligodendroglioma
57. Low-grade oligodendroglioma responds to chemotherapy
58. Long-term outcome of lowgrade oligodendroglioma and mixed glioma
59. Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma
60. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas
61. Clonal analysis of a case of multiple meningiomas using multiple molecular genetic approaches: Pathology case report
62. Association of breast cancer with meningioma
63. Secretory meningioma: Clinical, histologic, and immunohistochemical findings in 31 cases
64. Epidemiology and etiology of intracranial meningiomas: A review
65. Cytogenetic, molecular genetic and pathological analyses in 126 meningiomas
66. Meningiomas: The decision not to operate
67. The natural history of asymptomatic meningiomas in Olmsted County, Minnesota
68. Fractionated radiation therapy in the treatment of intracranial meningiomas: Local control, functional efficacy, and tolerance in 91 patients
69. Long-term outcomes after meningioma radiosurgery: Physician and patient perspectives
70. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea
71. Adjuvant combined modality therapy for malignant meningiomas
72. Malignant meningioma: An indication for initial aggressive surgery and adjuvant radiotherapy
73. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000?
74. Epidemiology of primary CNS lymphoma
75. Primary central nervous system lymphoma: From clinical presentation to diagnosis
76. Primary intracerebral malignant lymphoma: Report of 248 cases
77. Primary central nervous system lymphoma
78. Primary CNS lymphoma: Treatment with combined chemotherapy and radiotherapy
79. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series
80. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas
81. Primary central nervous system non-Hodgkin's lymphoma: Survival advantages with combined initial therapy?
82. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine and dexamethasone for primary CNS lymphomas: Initial report of Radiation Therapy Oncology Group protocol 88-06
83. Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315
84. Long-term survival in primary CNS lymphoma
85. Primary central nervous system lymphoma